Biotech Startups

ClinCloud provides cloud-based solutions for collecting clinical trial data, aimed at improving the efficiency of data collection in drug development for pharmaceutical companies and research institutions. It also runs a CRO business covering data management and statistical analysis, and is based in Tokyo, Japan.

1 investor

Kolagen Pharma develops and sells pharmaceuticals, medical devices, and research reagents, and manufactures cosmetics, focusing on collagen-based biomaterials for regenerative medicine. Founded by university researchers in science and pharmacology, it is based within Kyoto University's medical research facilities in Japan.

1 investor

CellGen Tech develops cell-based medicines for rare and intractable diseases by engineering human adipose cells to produce therapeutic proteins. The company focuses on treating conditions caused by missing or deficient enzymes and proteins, with partnerships involving university medical experts.

1 investor

Cellspect develops next-generation clinical diagnostic reagents and in-vitro diagnostic products based on deep-tech, covering diagnostic technologies from biomarker discovery to treatment monitoring. It offers open-innovation partnerships with pharmaceutical companies and medical institutions, including point-of-testing and precision oncology products, based in Iwate, Japan.

1 investor

T Cell Nouveau develops Hybrid CAR-T cell therapies designed to treat solid tumors by enhancing immune system activation in suppressive tumor microenvironments. The clinical-stage biopharmaceutical company targets cancer patients and originated from research conducted at Mie University's Personalized Cancer Immunotherapy department.

1 investor

Tokiwa Bio develops the Stealth-type RNA vector (SRV™), a non-integrating gene delivery vector that can introduce multiple or large genes into cells at high efficiency for gene therapy. The company also applies SRV™ to cell reprogramming for regenerative medicine and to biopharmaceutical manufacturing.

1 investor

Nagasuna Mayu develops and manufactures silk protein products (sericin and fibroin) for application in cosmetics, healthcare, and materials, along with textile refining machinery. The company operates multiple facilities in Kyoto Prefecture, Japan, focusing on innovation in silk-based biotechnology.

1 investor

Human Life Code develops and commercializes novel therapeutics in specialty care areas such as cancer, autoimmune diseases, and retinal diseases. The company specializes in research, development, market launch, and lifecycle management of pharmaceutical products and regenerative medicine products.

1 investor

PharmaBio is Japan's first contract development and manufacturing organization (CDMO) for regenerative medicine and cell-based therapeutics. The company provides regulatory development support and manufacturing services for cell and tissue-derived pharmaceuticals.

1 investor

A biotech company specializing in high-density mass cultivation of stem cells, developing safe and compact culture devices and therapeutic cultivation technologies for clinical use based on non-woven scaffold technology.

1 investor

Kamui Pharma develops therapeutic compounds derived from probiotics for treating inflammatory bowel disease and other diseases. The company conducts drug discovery research and clinical trials focused on novel bioactive molecules.

1 investor

A company with expertise in developing pharmaceutical products through clinical trial phases (IND to NDA/BLA) and launching them for patients in Japan and Asia.

1 investor

PorMedTec develops transplantable organs and tissues using genetically modified pigs for manufacturing and commercializing as regenerative medicine products. The company targets patients and healthcare systems facing severe organ shortages by providing alternatives to dialysis and other symptom-based treatments.

1 investor

HoloBio is a Japanese molecular biology research company that studies the unique functions of region-specific plants, animals, and symbiotic microorganisms across Japan. It aims to discover and apply these biological functions to develop new technologies, while also supporting senior researchers in launching ventures.

1 investor

MiRNDa, Inc. is a Japanese biotech company developing in-vitro diagnostic (IVD) medical devices based on RNA modification technology to detect an early "stage 0" of cancer.

1 investor

United Immunity develops a myeloid-targeting platform using pullulan-based nanoparticles to selectively deliver therapeutic agents and vaccine antigens to macrophages and dendritic cells. The platform targets these immune cells through DC-SIGN receptor binding for cancer immunotherapy, vaccines, and treatment of fibrosis, viral infections, and inflammatory diseases.

1 investor

A company developing radioactive pharmaceuticals for cancer treatment with enhanced visibility. The company focuses on accelerating the delivery of innovative diagnostic and therapeutic agents to patients and healthcare providers.

1 investor

EditGene is an educational platform that explains gene and genome editing technologies such as CRISPR, base editing, and prime editing. It offers scientific resources for learners to understand DNA biology, editing mechanisms, and applications in biotechnology and medicine.

1 investor

TaiMed Biologics is a Taiwan-based biopharmaceutical company that develops monoclonal antibody therapies for HIV, including the long-acting TMB-365/TMB-380 combination and the CD4-targeted ADC platform extending into autoimmune diseases. It also operates a cGMP protein manufacturing facility and provides CDMO services such as process development, analytical method development, formulation development, and commercial manufacturing for antibody products.

1 investor

KBP Biosciences is a biotechnology research and development organization that discovers and develops innovative therapeutic drugs for unmet medical needs using an integrated discovery and development platform.

1 investor

Shanghai Jizhi Biochemical is a reagent company specializing in the research and development of biochemical reagents and life science products. The company serves laboratory professionals and scientific research institutions.

1 investor

A research-driven specialty pharmaceutical company that develops and commercializes innovative medicines through the 505(b)(2) regulatory pathway, focusing on central nervous system disorders, metabolic diseases, and orphan indications. The company operates in New Jersey and Shanghai, leveraging established molecules with proven safety profiles.

1 investor

Miyatani Natural Science Laboratory isolates and cultures probiotics such as yeast (for sake, beer, and wine), plant-based lactic acid bacteria, and filamentous fungi, providing them on request extracted from customer-specified media like plants or soil. The company, based in Japan, focuses on fermentation research to create new flavors, aromas, and functional microorganisms.

1 investor

Pharmaron provides drug research and development services globally, supporting the discovery and development of pharmaceutical therapies through integrated capabilities across multiple geographic regions.

1 investor